Thyrotropin (TSH)-secreting pituitary adenoma is a very rare disease. In one-quarter of patients suffering from this disease, the pituitary tumor secretes other anterior pituitary hormones. Herein, we report a case of pituitary adenoma with simultaneous secretion of TSH and growth hormone (GH). A 34-year-old female visitied local hospital complaining of sweating, intermittent palpitation, and weight loss of 8 kg within 1 year. The patient had undergone trans-sphenoidal surgery 3 years prior for resolution of a TSH and GH co-secreting pituitary adenoma. She had been administered somatostatin analogue prior to visiting our hospital. The patient's GH levels were suppressed to below 1 ng/mL on the 75 g oral glucose tolerance test, and her basal insulin-like growth factor-I (IGF-I) level was within normal range. Thyroid function tests demonstrated increased levels of both free thyroxine and TSH. Sella-MRI revealed pituitary adenoma at the floor of the pituitary fossa, approximately 2 cm in height. Therefore, she was diagnosed with residual TSH-secreting pituitary adenoma. The patient again underwent trans-sphenoidal surgery and entered complete remission, based on hormone levels and MRI findings. (Endocrinol Metab 26:160-165, 2011) 
INTRODUCTION
Thyrotropin (TSH)-secreting pituitary adenomas (TSHomas) are very rare pituitary tumors accounting for less than 2% of all pituitary adenomas [1, 2] . TSH-secreting pituitary adenoma (TSHoma) is usually diagnosed when free thyroxine (T4) levels are elevated in the presence of normal to high serum TSH concentration, combined with the presence of a pituitary adenoma [1, 2] . The first case of TSHoma was reported in 1960 by measuring serum TSH levels with a bioassay [3] , and so far about 350 cases of TSHoma have been reported [4] . Although most benign TSHomas secrete TSH alone, about onefourth of TSHomas simultaneously secrete TSH and other anterior pituitary hormones. Growth hormone (GH) is the most common co-secreted hormone with TSH (16%), followed by prolactin (PRL) (10.4%) and gonadotropins [2] . Approximately 59 cases of mixed TSH and GH-secreting pituitary adenomas (TSH/GH-omas) and 41 cases of mixed TSH and PRL-secreting pituitary adenomas have been reported [5] . Herein, we report a case of pituitary adenoma with simultaneous secretion of TSH and GH, which was not controlled after trans-sphenoidal surgery (TSA) with long-term somatostatin analogue therapy.
CASE REPORT
A 34-year-old female visited the hospital complaining of sweating, intermittent palpitation, and weight loss of 8 kg within 1 year.
Three years ago, she took a medical examination and was referred to a tertiary hospital for hyperthyroidism with goiter. In magnetic resonance imaging (MRI), huge pituitary adenoma was shown (Fig.   1A , upper panel). She was diagnosed with TSH/GH-oma and underwent TSA. The pituitary tumor was positive to GH, TSH, and PRL on immunohistochemical staining. Plasma insulin-like growth factor-I (IGF-I) levels was normalized after surgery (from 514.5 ng/mL to 233.6 ng/mL; normal, 79-384 ng/mL), but GH was not suppressed to below 1 ng/mL on 75 g oral glucose tolerance test (1.25 ng/mL).
Both free T4 and TSH levels were elevated before the surgery and decreased after the surgery for 10 months. Prior to the surgery, free T4 was 2.49 ng/dL (normal, 0.89-1.78 ng/dL) and TSH was 8.0 μIU/ mL (normal, 0.17-4.05 μIU/mL). After the surgery, free T4 decreased http://www.enm-kes.org to 1.26 ng/dL, and TSH to 2.09 μIU/mL. However, both free T4 and TSH increased 10 months after TSA and peaked to 2.78 ng/dL and 6.3 μIU/mL at 16 months after TSA, respectively. She had been administered long-acting somatostatin analogues (lanreotide SR 60 mg subcutaneous injection, monthly) for 34 months before coming to the hospital. She complained of sweating and intermittent palpitation after the surgery and underwent weight loss of 8 kg over 1 year.
She was referred to the hospital for persistently elevated free T4 and TSH levels and symptoms as mentioned above. On admission, her vital signs were as follows: body temperature, 37.2°C; pulse rate 85 beats per minute; blood pressure 119/72 mmHg. Her height and body weight were 158 cm and 54 kg, respectively. Physical examination revealed diffuse goiter without palpable mass, tenderness, or bruit. Primary and secondary sexual developments were normal.
There was no tremor or visual defect on the visual field test. Neither ophthalmopathy nor pretibial myxedema was noted.
A complete blood count showed hemoglobin 11.5 g/dL, hematocrit 35.6%, white blood cell count 4870/mL, and platelet count 217,000/ mL. Other laboratory tests were within normal range. GH was suppressed to 0.58 ng/mL (normal, 0-9.5 ng/mL) on 75 g oral glucose tolerance test (Table 1) Table 2 ).
The chest X-ray was normal without evidence of hilar lymphade- 
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1st TSA before and after 2nd TSA before and after GH normal, 0-9.5 ng/mL. GH, growth hormone. Hyperthyroidism was controlled by methimazole of 10 mg per day before surgery. During the operation, fibrotic adhesion and bulging tumor was identified on the floor side. Tumor, which showed yellowish color and slid nature, was penetrating the sphenoid floor bone. Tumor was adherent on the normal pituitary gland and was separated by dissection. After adenomectomy, total resection of tumor was confirmed using an endoscope. Pathologic finding revealed a solid chromophobe adenoma. Immunohistochemical staining results were positive to TSH and GH and negative to PRL (Fig. 2) . After the second TSA, MRI showed no residual pituitary tumor (Fig. 1B, lower panel). On the third day after surgery, serum free T4 and TSH levels were normalized also (0.87 ng/dL and 2.40 μIU/mL, respectively) (Fig. 3) . She had complete remission, based on hormone levels and MRI findings.
DISCUSSION
TSHomas are very rare pituitary tumors with the prevalence of one case per million [1, 2] . The first case of TSHoma was reported in 1960 by measuring the serum TSH levels with a bioassay [3] . The first case of TSHoma by measuring TSH by RIA was reported in TSHoma indiscriminately affects men and women [4] . Most patients with TSHoma are diagnosed in the fifth-sixth decade. However, TSHoma could occur at any age (ranging from 11 to 84 years) [5, 7] . TSH levels have no correlation with tumor size [7] . Clinical features vary according to the excessive thyroid hormone and mass effects of the expanding tumor. The most common findings are goiter (more than 90% of patients) and thyrotoxicosis (70% of patients) [2] . In approximately half of patients, presenting symptoms include fatigue, tremor, heat intolerance, weight loss, and diarrhea [4] . Ophthalmopathy, pretibial myxedema, and acropachy are absent [7] .
Symptoms due to mass effect, such as visual field defect and headache are present in more than 20% of patients [2] . Menstrual disorders, galactorrhea and acromegalic features may be present at diagnosis [2, 7] . In patients with TSHoma with co-secreted GH, typical features of acromegaly may make physicians to overlook the importance of evaluating thyroid function and related symptoms [4] .
Our patient was initially recognized by goiter, and acromegalic features were unusually not prominent. After the first TSA, she complained of symptoms associated with thyrotoxicosis. However, ophthalmopathy and pretibial myxedema were not present.
In patients with TSHoma, free T4 levels are elevated, but TSH is not suppressed, and such a condition is called inappropriate TSH secretion [1, 2] . Absent or impaired TSH responses to TRH stimulation test are shown in TSHoma [7] . In TSHomas, the hormonal feedback caused by changes in level of peripheral thyroid hormone differs from that in normal condition. Although the negative feedback is impaired, the positive feedback by decrements of thyroid hormone levels is intact or increased [8] . Even with a small reduction of circulating thyroid hormone, the level of TSH can increase abruptly.
In our case, the serum TSH level increased rapidly even with the short-term treatment of methimazole (Fig. 3) . As TSHomas are often accompanied by hypersecretion of α-subunit, the molar ratio of α-subunit to TSH is one of the diagnostic clues. The molar ratio is calculated using a formula, (α-subunit in μg/L divided by TSH in mU/ L) × 10, and an increased molar ratio favors the presence of TSHoma [1, 7] . However, in our patient, α-subunit level was 0.49 mIU/mL (normal, 0-0.9 mIU/mL), and molar ratio was very low (0.01). Some cases of TSHomas with low α-subunit level were also reported [9, 10] . These results suggest that increased α-subunit level or molar ratio is not always required for the diagnosis of TSHoma.
Most benign TSHomas secrete TSH alone, and about one-fourth of TSHomas simultaneously secrete TSH and other anterior pituitary hormones. GH is the most frequently co-secreted hormone with TSH (n = 59, 16% of all TSHoma cases) at present [5] . Other anterior pituitary hormones, which are co-secreted with TSH, are prolactin (10.4%) and seldom gonadotropins [2] . As somatotroph and lactotroph cells are known to share common transcription factors such as PROP-1, Pit1 and HESX-1 with thyrotrophs, TSHomas seem to be frequently associated with concomitant hypersecretion of GH or PRL [11, 12] . In our case, only TSH and GH levels were elevated in plasma, but immunohistochemical staining was positive to PRL, as well as TSH and GH at first.
TSHoma should be differentiated from resistance to thyroid hor- Trans-sphenoidal or subfrontal adenomectomy is the first choice to treat TSHomas [2] . However, this may be difficult because of an aggressive growth pattern. Thus, TSH-secreting adenomas are less easily controlled by surgery alone than other types of adenomas [7] . resistance to these analogues [1, 7] . Common side effects of these analogues are tachyphylaxis, cholelithiasis and carbohydrate intolerance and should be carefully monitored. Our patient received long-acting somatostatin analogue for more than 2 years, but TSH levels had never decreased to normal. Thus, this case might be considered as true resistance to this analogue.
Although there are no definite criteria for cure of TSHomas because of rarity of the disease, cure has been generally considered as normalization of TSH and the absence of visible tumor on MRI.
Pituitary imaging is recommended every 2-3 years after surgery [7] .
Losa et al. [20] have proposed the measurement of TSH levels 1-7 days after surgery. Normal thyrotrophs are still suppressed at that time, and measured TSH should reflect TSH levels secreted by the tumor. In our patient, TSH was evaluated before the surgery and subsequently after the surgery for 4 days. TSH level decreased from 10.53 μIU/mL to 2.40 μIU/mL over time.
In our case, the patient had taken TSA and received somatostatin analogue for a long time. Despite this combined treatment, TSH levels were continuously elevated. Moreover, the patient complained of symptoms, such as sweating, palpitation and weight loss. If she received repeated surgical treatment or radiotherapy earlier, her prognosis and quality of life might have been improved. After repeated surgical treatment, she was cured. Although TSHoma is a rare disease, it should be considered in patients with elevated free T4 levels with the presence of normal to high serum TSH concentration. First choice of treatment is TSA. However, most TSHomas show aggressive growth features, with which cure rate by surgery alone tends
